Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 27 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 10119143

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted

  2. US 10106792

    Methods and compositions for the specific inhibition of gene expression by double-stranded RNA

    INTEGRATED DNA TECHNOLOGIES, INC. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted

  3. US 10105523

    Implantable drug delivery device

    Nano Precision Medical, Inc. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted

  4. US 10106592

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted

  5. US 10100310

    Modulation of prekallikrein (PKK) expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted

  6. US 10100312

    Compositions and methods for inhibiting expression of TMPRSS6 gene

    Alnylam Pharmaceuticals, Inc. · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted

  7. US 10093745

    Anti-CSPG4 fusions with interferon for the treatment of malignancy

    The Regents of the University of California · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  8. US 10093708

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  9. US 10093900

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  10. US 10093899

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  11. US 10093790

    Three-dimensional cellulose molded body, method for the production thereof and use of the same

    LENZING AKTIENGESELLSCHAFT · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  12. US 10093742

    Multispecific GITR-binding fusion proteins and methods of use thereof

    Inhibrx, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  13. US 10086088

    Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord

    The Regents of the University of California · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted

  14. US 10080799

    Methods and compositions related to glycoprotein-immunoglobulin fusions

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted

  15. US 10077444

    Compositions and methods for inhibiting expression of the LECT2 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted

  16. US 10071123

    Treatment of pulmonary arterial hypertension with mesenchymal stem cells

    United Therapeutics Corporation · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted

  17. US 10058556

    Method of treatment of aggression

    Supernus Pharmaceuticals, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted

  18. US 10053706

    Parental RNAi suppression of chromatin remodeling genes to control coleopteran pests

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Aug 21, 2018 · Expires Aug 16, 2038

    granted

  19. US 10046024

    Cyclic-GluR6 analogs, methods of treatment and use

    The United States of America, as represented by National Institutes of Health (NIH), U.S. Dept of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resource (DEITR) · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted

  20. US 10047401

    Expression protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted

  21. US 10045943

    Implantable medical devices for extended release of therapeutic agents

    Nano Precision Medical, Inc. · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted

  22. US 10041053

    Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

    Precision BioSciences, Inc. · Granted Aug 7, 2018 · Expires Aug 2, 2038

    granted

  23. US 10034919

    Targeted human-interferon fusion proteins

    Universite Montepellier 2 · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted

  24. US 10023627

    Vascular endothelial growth factor fusion protein

    KOREA PRIME PHARM CO., LTD. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.